BioSpace News Archive

LEADER Trial Will Use Results from Foundation Medicine’s Comprehensive Genomic Profiling Tests to Screen for Actionable Driver Mutations to Inform Trial Enrollment and Targeted Therapy Options for Patients.

Vizgen , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced the closing of $85.2 million Series C financing.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline of the New Drug Application (NDA) for AMX0035.

Dyne Therapeutics, Inc . (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference being held in New York, NY on Thursday, June 9, 2022 at 3:00 p.m. ET.

COBALT study in advanced PBC, previously terminated early due to feasibility challenges, did not demonstrate a statistically significant difference in clinical endpoints between Ocaliva ® and placebo HEROES-US real-world analysis demonstrated statistically significant improvement in event-free survival in patients receiving Ocaliva for PBC,

IHL-42X reduced primary endpoint apnoea hypopnea index relative to baseline at all three doses that were assessed Low dose IHL-42X exhibited superior safety and efficacy metrics to mid and high doses.

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Jason Rhodes, partner at Atlas Venture, has resigned from the company’s Board of Directors.

Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Company’s Board of Directors approved the grant of stock options to purchase, an aggregate of 266,000 shares of the Company’s common stock, to five new employees on June 1, 2022.

Attralus, Inc., today announced that final data from the University of Tennessee Graduate School of Medicine from its Phase 1/2 trial of iodine evuzamitide (124I-AT-01), will be presented in both oral and poster presentations at the 2022 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting.

Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today presented positive Phase 3 data for BIIB800 (BAT1806), a biosimilar candidate referencing ACTEMRA®/ROACTEMRA® (tocilizumab), anti-interleukin-6 receptor monoclonal antibody, at the Annual European Congress of Rheumatology (EULAR 2022).